Association of CYP2C19 gene single nucleotide polymorphisms (rs12248560 and rs4244285) with response to thalidomide in transfusion dependent β-thalassemia patients- a 12-months follow-up study | Synapse
March 3, 2026Open Access
Association of CYP2C19 gene single nucleotide polymorphisms (rs12248560 and rs4244285) with response to thalidomide in transfusion dependent β-thalassemia patients- a 12-months follow-up study
Key Points
Thalidomide shows effectiveness in improving treatment response for transfusion dependent β-thalassemia patients.
CYP2C19 gene variants rs12248560 and rs4244285 are linked to the treatment outcomes observed in these patients.
Follow-up study conducted over 12 months provides insights into genetic influences on therapy effectiveness.
Individualized treatment may enhance outcomes, highlighting the importance of genetic testing for therapy optimization.
Abstract
The findings suggest thalidomide as an effective option for TDT and highlight the potential role of CYP2C19 genetic variation in modulating treatment response.